Celldex to Participate in Upcoming November Investor Conferences
10 Nov 2022
Antibody
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:
Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ET
Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMT
Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.m. ET
Webcasts of the presentations will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.